8-K: CareDx Reports Strong Q4, Full Year 2025 Preliminary Results

CareDx announced preliminary unaudited financial results for Q4 and full year 2025, reporting significant revenue growth across all segments.

Summary

• CareDx reported preliminary unaudited revenue of approximately $108 million for the fourth quarter of 2025, marking a 25% year-over-year increase.
• Testing services revenue for Q4 2025 reached approximately $78 million, up 23% year-over-year, with testing services volume increasing by 17% to approximately 53,000.
• Patient & digital solutions revenue grew 47% year-over-year to approximately $17 million in Q4 2025, while product revenue increased 17% to approximately $13 million.
• For the full year 2025, CareDx achieved preliminary unaudited revenue of approximately $380 million, representing a 14% year-over-year increase.
• Full year testing services revenue was approximately $274 million (up 10% YoY) with volume of approximately 200,000 (up 14% YoY).
• Patient & digital solutions revenue for the full year grew 31% to approximately $57 million, and product revenue increased 19% to approximately $48 million.
• The company held approximately $200 million in cash, cash equivalents, and marketable securities as of December 31, 2025.
• CareDx repurchased $12 million worth of shares (773,000 shares at an average price of $15.79) during Q4 2025, contributing to a total of $88 million in share repurchases (5.8 million shares at an average price of $15.16) for the full year 2025.

Sentiment

Score: 9

Explanation: The filing presents exceptionally strong preliminary financial results with significant year-over-year growth across all key metrics and segments. The company's healthy cash position and substantial share repurchases further underscore financial strength and confidence, indicating a very positive outlook.

Positives

• Strong preliminary Q4 2025 revenue growth of 25% year-over-year, reaching approximately $108 million.
• Significant full year 2025 revenue growth of 14% year-over-year, totaling approximately $380 million.
• Consistent growth across all business segments, including testing services (23% Q4 YoY, 10% FY YoY), patient & digital solutions (47% Q4 YoY, 31% FY YoY), and product revenue (17% Q4 YoY, 19% FY YoY).
• Robust testing services volume growth of 17% in Q4 and 14% for the full year 2025.
• Healthy cash position with approximately $200 million in cash, cash equivalents, and marketable securities as of December 31, 2025.
• Active capital management demonstrated by $88 million in share repurchases during 2025, including $12 million in Q4.

Negatives

• The financial results are preliminary and unaudited, subject to adjustment upon completion of customary annual audit procedures.

Risks

• Forward-looking statements are subject to numerous risks and uncertainties that are difficult to predict and beyond the company's control.
• Potential for actual results to differ materially from projections due to general economic and market factors, and global economic and marketplace uncertainties.
• Risks and uncertainties are further discussed in the company's filings with the SEC, including the Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed on February 28, 2025.

Future Outlook

CareDx plans to build on its commercial momentum in 2026 and advance its Transplant+ innovation pipeline, indicating a continued focus on growth and product development.

Management Comments

• "We had another quarter of strong testing services volume growth and record revenue across all segments of our business."
• "Our solutions selling strategy is working."
• "In 2026, we plan to build on this commercial momentum and advance our Transplant+ innovation pipeline."

Industry Context

CareDx operates in the precision medicine sector, specifically focused on transplant patients. The reported strong revenue and volume growth across all segments suggest robust demand for its non-invasive molecular testing, laboratory products, and digital health solutions within the transplant community. This performance indicates the company is either gaining market share or benefiting from an expanding market for advanced transplant care solutions, aligning with broader trends towards personalized medicine and digital health integration in specialized medical fields.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or industry benchmarks to assess the results against global standards. Therefore, a direct comparison is not possible based solely on the provided information.

Stakeholder Impact

• Shareholders are positively impacted by strong financial performance, significant revenue growth, and substantial share repurchases, which can enhance shareholder value.
• Employees may benefit from the company's growth and expansion, potentially leading to increased opportunities.
• Customers (transplant patients and caregivers) are impacted by the continued advancement of the Transplant+ innovation pipeline and integrated solutions aimed at improving outcomes and organ health.

Next Steps

• Completion of customary annual audit procedures for the preliminary financial information.
• Building on commercial momentum in 2026.
• Advancing the Transplant+ innovation pipeline in 2026.

Key Dates

Recommendation

CareDx's preliminary Q4 and full year 2025 results demonstrate robust financial health and significant growth across all key segments, including testing services, patient & digital solutions, and product revenue. The substantial year-over-year revenue and volume increases, coupled with a strong cash position and aggressive share repurchase program, signal strong management confidence and effective strategy execution. The positive outlook for 2026, focusing on commercial momentum and innovation, further reinforces the company's growth trajectory. These factors collectively present a compelling investment case, suggesting the stock is likely to outperform.

Keywords

CareDx, CDNA, Transplant Company, precision medicine, financial results, Q4 2025, full year 2025, revenue growth, testing services, patient solutions, digital solutions, product revenue, share repurchase, cash position